Kröger Liisa, Vähäsalo Paula, Tynjälä Pirjo, Aalto Kristiina, Säilä Hanna, Malin Merja, Putto-Laurila Anne, Lahdenne Pekka
KYS, Lasten- ja nuorten klinikka ja Itä-Suomen Yliopisto.
Duodecim. 2012;128(5):477-86.
Although etiology of juvenile idiopathic arthritis (JIA) is currently not known, better understanding of immunologic pathways of inflammation and the development of new therapies with biologic agents have remarkably improved the treatment of JIA. However, approximately 30% of the patients with JIA do not seem to response adequately to conventional anti-rheumatic drugs but the arthritis runs a continuously active course and may lead to the evolution of erosions. Such patients benefit from biologic agents, of which the longest clinical experience comes from anti-TNF therapies. Molecules targeting IL-1, IL-6 and B- and T-lymphocytes are also used in the treatment of severe JIA.
虽然目前尚不清楚青少年特发性关节炎（JIA）的病因，但对炎症免疫途径的深入了解以及生物制剂新疗法的开发显著改善了JIA的治疗。然而，约30%的JIA患者似乎对传统抗风湿药物反应不佳，关节炎持续活动，可能导致关节侵蚀进展。这类患者可从生物制剂中获益，其中临床经验最丰富的是抗TNF治疗。靶向IL-1、IL-6以及B和T淋巴细胞的分子也用于治疗重度JIA。
